Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes - PubMed (original) (raw)
Comparative Study
Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes
J Fuhlendorff et al. Diabetes. 1998 Mar.
Abstract
The action of repaglinide, a novel insulin secretagogue, was compared with the sulfonylurea glibenclamide with regard to the hypoglycemic action in vivo, binding to betaTC-3 cells, insulin secretion from perifused mouse islets, and capacity to stimulate exocytosis by direct interaction with the secretory machinery in single voltage-clamped mouse beta-cells. Two binding sites were identified: a high-affinity repaglinide (KD = 3.6 nmol/l) site having lower affinity for glibenclamide (14.4 nmol/l) and one high-affinity glibenclamide (25 nmol/l) site having lower affinity for repaglinide (550 nmol/l). In contrast to glibenclamide, repaglinide (in concentrations as high as 5 micromol/l) lacked the ability to enhance exocytosis in voltage-clamped beta-cells. Repaglinide was more potent than glibenclamide in stimulating insulin release from perifused mouse islets (EC50 29 vs. 80 nmol/l). The greater potency of repaglinide in vitro was paralleled by similar actions in vivo. The ED50 values for the hypoglycemic action were determined to be 10.4 and 15.6 microg/kg after intravenous and oral administration, respectively. The corresponding values for glibenclamide were 70.3 microg/kg (intravenous) and 203.2 microg/kg (oral). Further, repaglinide (1 mg/kg p.o.) was effective (P < 0.001) as an insulin-releasing agent in a rat model (low-dose streptozotocin) of type 2 diabetes. These observations suggest that the insulinotropic actions of repaglinide and glibenclamide in vitro and in vivo are secondary to their binding to the high-affinity repaglinide site and that the insulinotropic action of repaglinide involves both distinct and common cellular mechanisms.
Similar articles
- Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
Hu S, Wang S, Fanelli B, Bell PA, Dunning BE, Geisse S, Schmitz R, Boettcher BR. Hu S, et al. J Pharmacol Exp Ther. 2000 May;293(2):444-52. J Pharmacol Exp Ther. 2000. PMID: 10773014 - Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
Abbink EJ, van der Wal PS, Sweep CG, Smits P, Tack CJ. Abbink EJ, et al. Diabetes Metab Res Rev. 2004 Nov-Dec;20(6):466-71. doi: 10.1002/dmrr.474. Diabetes Metab Res Rev. 2004. PMID: 15386823 Clinical Trial. - Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
Malaisse WJ. Malaisse WJ. Treat Endocrinol. 2003;2(6):401-14. doi: 10.2165/00024677-200302060-00004. Treat Endocrinol. 2003. PMID: 15981944 Review. - Mechanism of action of a new class of insulin secretagogues.
Malaisse WJ. Malaisse WJ. Exp Clin Endocrinol Diabetes. 1999;107 Suppl 4:S140-3. doi: 10.1055/s-0029-1212170. Exp Clin Endocrinol Diabetes. 1999. PMID: 10522840 Review.
Cited by
- In silico identification of structure requirement for novel thiazole and oxazole derivatives as potent fructose 1,6-bisphosphatase inhibitors.
Hao M, Zhang X, Ren H, Li Y, Zhang S, Luo F, Ji M, Li G, Yang L. Hao M, et al. Int J Mol Sci. 2011;12(11):8161-80. doi: 10.3390/ijms12118161. Epub 2011 Nov 18. Int J Mol Sci. 2011. PMID: 22174657 Free PMC article. - Assessment of in vivo and in vitro genotoxicity of glibenclamide in eukaryotic cells.
de Sant'Anna JR, Franco CC, Mathias PC, de Castro-Prado MA. de Sant'Anna JR, et al. PLoS One. 2015 Mar 24;10(3):e0120675. doi: 10.1371/journal.pone.0120675. eCollection 2015. PLoS One. 2015. PMID: 25803314 Free PMC article. - Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents.
Hunt MJ, Morton AJ. Hunt MJ, et al. Exp Brain Res. 2005 Oct;166(2):220-9. doi: 10.1007/s00221-005-2357-z. Epub 2005 Jul 21. Exp Brain Res. 2005. PMID: 16034568 - Pharmacogenetics: potential role in the treatment of diabetes and obesity.
Vella A, Camilleri M. Vella A, et al. Expert Opin Pharmacother. 2008 May;9(7):1109-19. doi: 10.1517/14656566.9.7.1109. Expert Opin Pharmacother. 2008. PMID: 18422469 Free PMC article. Review. - Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Ma J, Liu LY, Wu PH, Liao Y, Tao T, Liu W. Ma J, et al. J Diabetes Res. 2014;2014:294017. doi: 10.1155/2014/294017. Epub 2014 Mar 4. J Diabetes Res. 2014. PMID: 24772445 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical